Lord, Abbett & Co
ALXN

Lord, Abbett & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

Lord, Abbett & Co’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-57,273
Closed -$7.11M – 899
2018
Q2 		$7.11M Buy
57,273
+3,717
+7% +$434K 0.02% 679
2018
Q1 		$5.97M Sell
53,556
-142,534
-73% -$17M 0.02% 698
2017
Q4 		$23.4M Sell
196,090
-17,791
-8% -$2.17M 0.07% 429
2017
Q3 		$30M Buy
+213,881
New +$29.1M 0.09% 365
2016
Q1 		– Sell
-229,415
Closed -$43.8M – 970
2015
Q4 		$43.8M Buy
229,415
+160,287
+232% +$28M 0.13% 241
2015
Q3 		$10.8M Sell
69,128
-23,051
-25% -$4.2M 0.03% 571
2015
Q2 		$16.7M Sell
92,179
-40,150
-30% -$6.93M 0.04% 535
2015
Q1 		$22.9M Sell
132,329
-15,830
-11% -$2.87M 0.06% 450
2014
Q4 		$27.4M Buy
148,159
+87,210
+143% +$16.2M 0.07% 396
2014
Q3 		$10.1M Sell
60,949
-3,443
-5% -$565K 0.03% 599
2014
Q2 		$10.1M Buy
+64,392
New +$10.2M 0.02% 640
2014
Q1 		– Sell
-51,668
Closed -$6.88M – 1097
2013
Q4 		$6.88M Buy
+51,668
New +$6.2M 0.02% 755

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Lord, Abbett & Co's ALXN Position: Q3 2018 in Review

Lord, Abbett & Co sold out of Alexion Pharmaceuticals (ALXN) in Q3 2018, closing a stake of 57,273 shares — an estimated $7.11M sold.

Lord, Abbett & Co first reported a position in ALXN in Q4 2013 and held it in 12 quarters. The position peaked at $43.8M in Q4 2015. 585 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

  • Lord, Abbett & Co reported no remaining Alexion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Lord, Abbett & Co sold 57,273 Alexion Pharmaceuticals shares in Q3 2018, an estimated $7.11M.
  • Lord, Abbett & Co first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 12 quarters.
  • Lord, Abbett & Co's Alexion Pharmaceuticals position peaked at $43.8M in Q4 2015.
  • 585 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on Lord, Abbett & Co's 13F filing for Q3 2018, filed 14 Nov 2018.